Using functional MYCN synthetic lethal metabolic and genetic screens, we further identified cyst(e)ine deprivation and glutathione peroxidase 4 (GPX4) inhibition as selective liabilities in MYCN-amplified neuroblastomas. This evidence concerns the gene MYCN and neuroblastoma.